Korean Drug Co., Ltd. (KOSDAQ:014570)
4,575.00
+110.00 (2.46%)
Last updated: Apr 1, 2025
Korean Drug Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 2,995 | -4,917 | 11,809 | 9,042 | 7,360 | Upgrade
|
Depreciation & Amortization | 2,069 | 1,749 | 1,383 | 1,470 | 1,355 | Upgrade
|
Loss (Gain) From Sale of Assets | -3.56 | 3.68 | -2.81 | -1.13 | 5.28 | Upgrade
|
Loss (Gain) From Sale of Investments | -72.9 | -132.87 | 383.6 | 359.46 | 1,534 | Upgrade
|
Loss (Gain) on Equity Investments | - | - | - | - | 576.86 | Upgrade
|
Other Operating Activities | -513.96 | 2,118 | -801.33 | 1,384 | 1,491 | Upgrade
|
Change in Accounts Receivable | 4,806 | 3,566 | -1,390 | -948.64 | 872.88 | Upgrade
|
Change in Inventory | -1,605 | -4,657 | -971.78 | -2,149 | 1,030 | Upgrade
|
Change in Accounts Payable | -1,351 | 1,916 | -3,208 | 550.5 | -403.67 | Upgrade
|
Change in Other Net Operating Assets | -1,455 | -1,645 | -1,288 | -900.83 | -1,492 | Upgrade
|
Operating Cash Flow | 4,869 | -1,999 | 5,913 | 8,806 | 12,330 | Upgrade
|
Operating Cash Flow Growth | - | - | -32.86% | -28.58% | 98.60% | Upgrade
|
Capital Expenditures | -1,027 | -120.7 | -6,093 | -1,146 | -738.47 | Upgrade
|
Sale of Property, Plant & Equipment | 7.46 | 1.12 | 5.86 | 4.5 | - | Upgrade
|
Sale (Purchase) of Intangibles | -15.71 | -466.7 | -384.22 | 157.73 | 219.04 | Upgrade
|
Investment in Securities | -9,830 | 18,159 | 894.66 | -6,980 | -9,911 | Upgrade
|
Other Investing Activities | -23.96 | -5,299 | 175 | -291 | 140 | Upgrade
|
Investing Cash Flow | -10,889 | 12,274 | -5,401 | -8,254 | -10,290 | Upgrade
|
Long-Term Debt Repaid | -88.34 | -82.46 | -76.55 | -75.69 | -81.97 | Upgrade
|
Total Debt Repaid | -88.34 | -82.46 | -76.55 | -75.69 | -81.97 | Upgrade
|
Net Debt Issued (Repaid) | -88.34 | -82.46 | -76.55 | -75.69 | -81.97 | Upgrade
|
Issuance of Common Stock | 133.7 | 18.31 | 3.61 | 24.01 | 10.01 | Upgrade
|
Repurchase of Common Stock | - | - | - | -1,103 | - | Upgrade
|
Dividends Paid | -1,618 | -1,941 | -1,833 | -1,634 | -1,089 | Upgrade
|
Other Financing Activities | - | - | 0 | 0 | - | Upgrade
|
Financing Cash Flow | -1,573 | -2,005 | -1,906 | -2,789 | -1,161 | Upgrade
|
Foreign Exchange Rate Adjustments | 6.89 | -7.09 | -20.34 | 10.95 | -81.16 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | 0 | - | - | -0 | Upgrade
|
Net Cash Flow | -7,586 | 8,263 | -1,415 | -2,227 | 797.4 | Upgrade
|
Free Cash Flow | 3,842 | -2,119 | -180.15 | 7,660 | 11,592 | Upgrade
|
Free Cash Flow Growth | - | - | - | -33.92% | 267.27% | Upgrade
|
Free Cash Flow Margin | 5.26% | -2.60% | -0.22% | 10.29% | 17.36% | Upgrade
|
Free Cash Flow Per Share | 356.60 | -196.54 | -16.71 | 701.43 | 1066.29 | Upgrade
|
Cash Interest Paid | 4.24 | 3.02 | 2.1 | 1.53 | 3.13 | Upgrade
|
Cash Income Tax Paid | 3,792 | 12,140 | 3,383 | 2,274 | 840.74 | Upgrade
|
Levered Free Cash Flow | 3,630 | 7,388 | -2,709 | 6,243 | 9,411 | Upgrade
|
Unlevered Free Cash Flow | 3,632 | 7,390 | -2,707 | 6,244 | 9,413 | Upgrade
|
Change in Net Working Capital | -40.43 | -2,029 | 6,569 | 1,279 | -1,678 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.